CompaniesEli Lilly and CoFollowGilead Sciences IncFollowOct 4 (Reuters) – Eli Lilly and Co (LLY.N) on Wednesday appointed a new chief for
Mounjaro, chemically known as tirzepatide, is already being prescribed by doctors off-label as an obesity treatment.
Patrik Jonsson, the
In his new role, Jonsson will oversee Lilly’s launched products and late-stage development of diabetes and obesity treatments, including tirzepatide and other candidates such as its next-generation obesity drug retatrutide and obesity pill orforglipron.
Jonsson spent 33 years with the drugmaker, and has previously
Mason, who has also spent more than three decades with Lilly, oversaw
The diabetes drug, which clocked in sales of $979.7 million in the latest quarter, belongs to a class of drugs known as GLP-1s that stimulate insulin production.
GLP-1s have kick-started a market for obesity drugs that is estimated to
Lilly’s chief scientific officer Daniel Skovronsky will take on the additional responsibility to lead Lilly’s immunology division from Jonsson.
The company’s shares were
Reporting by Bhanvi Satija in Bengaluru; Editing by Savio D’Souza and Sherry Jacob-Phillips
Our Standards: The Thomson Reuters Trust Principles. Acquire Licensing Rights, opens new tab
Link from www.reuters.com